Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 14M | 87.7% |
| Gross Profit | 11M | 74.5% |
| Cost of Revenue | 2.5M | 184.5% |
| Operating expense | 43M | 16.8% |
| Net Income | -30M | 36.2% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 131M | 17.4% |
| Total Liabilities | 202M | 3.1% |
| Shares Outstanding | 1.59B | 518.7% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -35M | 47.8% |
| Cash from financing | 1.7M | 106.5% |
EPS
Financial Highlights for Adaptimmune Therapeutics in Q2 '25
Adaptimmune Therapeutics reported a revenue of 14M, which is a 87.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 11M, marking a 74.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.5M, a 184.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 43M, showing a -16.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -30M, showing a 36.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Adaptimmune Therapeutics with growth in revenue, gross profit, and net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
